JP2024512558A - 黒色腫のための組み合わせ治療 - Google Patents

黒色腫のための組み合わせ治療 Download PDF

Info

Publication number
JP2024512558A
JP2024512558A JP2023558347A JP2023558347A JP2024512558A JP 2024512558 A JP2024512558 A JP 2024512558A JP 2023558347 A JP2023558347 A JP 2023558347A JP 2023558347 A JP2023558347 A JP 2023558347A JP 2024512558 A JP2024512558 A JP 2024512558A
Authority
JP
Japan
Prior art keywords
combination
melanoma
inhibitor
treatment
months
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023558347A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024512558A5 (https=
Inventor
アンドリュー スミス，サイモン
ジェイン ディーン，エマ
イ，ジユン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of JP2024512558A publication Critical patent/JP2024512558A/ja
Publication of JP2024512558A5 publication Critical patent/JP2024512558A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2023558347A 2021-03-26 2022-03-25 黒色腫のための組み合わせ治療 Pending JP2024512558A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163166295P 2021-03-26 2021-03-26
US63/166,295 2021-03-26
US202163208728P 2021-06-09 2021-06-09
US63/208,728 2021-06-09
PCT/EP2022/057895 WO2022200557A1 (en) 2021-03-26 2022-03-25 Combination treatments for melanoma

Publications (2)

Publication Number Publication Date
JP2024512558A true JP2024512558A (ja) 2024-03-19
JP2024512558A5 JP2024512558A5 (https=) 2025-04-02

Family

ID=81449142

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023558347A Pending JP2024512558A (ja) 2021-03-26 2022-03-25 黒色腫のための組み合わせ治療

Country Status (11)

Country Link
US (1) US20240197748A1 (https=)
EP (1) EP4313057A1 (https=)
JP (1) JP2024512558A (https=)
KR (1) KR20230162030A (https=)
AU (2) AU2022245277B8 (https=)
BR (1) BR112023019433A2 (https=)
CA (1) CA3213407A1 (https=)
IL (1) IL306028A (https=)
MX (1) MX2023011332A (https=)
TW (1) TW202304458A (https=)
WO (1) WO2022200557A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL297842A (en) * 2020-05-11 2023-01-01 Astrazeneca Ab ATR inhibitors for cancer treatment
WO2025233224A1 (en) * 2024-05-09 2025-11-13 F. Hoffmann-La Roche Ag Use of atr inhibitors in combination with anti-pd(l)1 therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
PL2504364T3 (pl) 2009-11-24 2017-12-29 Medimmune Limited Ukierunkowane środki wiążące przeciwko B7-H1
SA111320519B1 (ar) 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
WO2015036499A1 (en) * 2013-09-11 2015-03-19 Medimmune Limited Anti-b7-h1 antibodies for treating tumors
IL297842A (en) * 2020-05-11 2023-01-01 Astrazeneca Ab ATR inhibitors for cancer treatment

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CANCER RES., vol. 78 (13_Supplement), JPN6026013677, 2018, pages 026, ISSN: 0005834546 *
CANCER RES., vol. 79 (13_Supplement), JPN6026013678, 2019, pages 2269, ISSN: 0005834547 *
STUDY NCT03780608 ON DATE: 2019.12.26 (V3)，HISTORY OF CHANGES FOR STUDY: NCT03780608，CLINICALTRIAL, JPN6026013679, 26 December 2019 (2019-12-26), ISSN: 0005834548 *

Also Published As

Publication number Publication date
IL306028A (en) 2023-11-01
WO2022200557A1 (en) 2022-09-29
KR20230162030A (ko) 2023-11-28
CA3213407A1 (en) 2022-09-29
AU2025252564A1 (en) 2025-11-27
MX2023011332A (es) 2023-10-03
US20240197748A1 (en) 2024-06-20
EP4313057A1 (en) 2024-02-07
AU2022245277A9 (en) 2023-11-16
TW202304458A (zh) 2023-02-01
AU2022245277B1 (en) 2025-07-17
AU2022245277A1 (en) 2023-11-02
BR112023019433A2 (pt) 2023-10-24
AU2022245277B8 (en) 2025-08-07

Similar Documents

Publication Publication Date Title
EP4149455B1 (en) Combination of the atr inhibitor azd6738 and paclitaxel for use in treating melanoma in patients who previously received immunotherapy
US20250154274A1 (en) Use of anti-pd-1 antibody in combination with anti-cd27 antibody in cancer treatment
JP2022518236A (ja) 進行期固形腫瘍がんに対する治療用ｒｎａおよび抗ｐｄ１抗体
KR20180027576A (ko) 면역 체크포인트 억제제를 사용하여 암을 치료하는 방법
KR20180101584A (ko) 항-pd-1 항체 및 또 다른 항암제의 조합을 사용하는 폐암의 치료
AU2025252564A1 (en) Combination treatments for melanoma
CN109153722A (zh) 用于治疗癌症的方法
JP2022518235A (ja) 進行期固形腫瘍がんの治療用ｒｎａ
JP2020511535A (ja) 中枢神経系（ｃｎｓ）がんを治療するためのプロテアソーム阻害剤の利用
JP2025529196A (ja) 間葉系上皮転換因子（ｍｅｔ）標的薬を使用して非小細胞肺がんを治療する方法
EA052375B1 (ru) Варианты комбинированного лечения меланомы
CN117098539A (zh) 用于黑色素瘤的组合治疗
Subudhi A pilot trial to explore the link between immunological changes, efficacy, safety and tolerability of durvalumab (MEDI4736) plus tremelimumab in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (CRPC)
WO2025212469A1 (en) Use of an immunoconjugate for the treatment of gastric cancer
KR20240162547A (ko) 화학요법과 조합하여 항-pd-l1 항체를 사용하여 담도암을 치료하는 방법
WO2026006138A1 (en) Combination therapy comprising an immunoconjugate for the treatment of gastroesophageal cancer
JP2026513665A (ja) Ａｚｄ５３０５の投与レジメント
WO2025259644A1 (en) Use of an immunoconjugate for the treatment of gastroesophageal cancer
CN120957724A (zh) 索托拉西布/卡铂/培美曲塞在癌症治疗中的剂量方案
AU2023249636A1 (en) Treatment of solid tumors
JP2023536620A (ja) Ｃｌｌの治療
Smyth et al. Clinical Trial Registration: The trial is registered with www. ClinicalTrials. gov, identifier: NCT03443856.

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250324

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250324

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260407